Pfizer Is A Good Stock To Buy After The Earnings
Summary: PFE has beaten analyst estimate both top- and bottom line. The firm has also
Summary: PFE has beaten analyst estimate both top- and bottom line. The firm has also
Summary: Pfizer scored a double beat on revenue and adjusted EPS, bolstered by the surprising
Summary: Despite today’s fall in Pfizer’s share price, it beat my and Wall Street analysts’
Summary: Pfizer’s Q3 earnings smashed analysts’ expectations, driven by a significant increase in COVID-related revenues,
Summary: There’s some rumbling going on within Pfizer’s investment community, as an activist hedge fund
Summary: Pfizer’s Q3 consensus estimate is likely to be exceeded as the successful integration of
Summary: Pfizer’s deep valuation and large dividend yield make it an attractive investment, despite potential
Summary: The story of activist fund Starboard Value taking a $1 billion position in Pfizer
Summary: Pfizer, yielding 5.6%, is an Ultra SWAN bargain with upside potential in the next
Summary: Pfizer’s stock has likely bottomed and shows strong technical and fundamental indicators, including a